Zacks Research Has Negative Outlook of IOVA FY2026 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Equities research analysts at Zacks Research cut their FY2026 earnings per share estimates for shares of Iovance Biotherapeutics in a report released on Friday, June 26th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings per share of ($0.72) for the year, down from their prior estimate of ($0.71). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.62) per share. Zacks Research also issued estimates for Iovance Biotherapeutics’ Q4 2026 earnings at ($0.18) EPS.

Several other equities research analysts have also issued reports on the stock. Truist Financial raised shares of Iovance Biotherapeutics to a “hold” rating in a report on Wednesday, March 25th. UBS Group lifted their price target on shares of Iovance Biotherapeutics from $2.00 to $4.00 and gave the company a “neutral” rating in a report on Thursday, March 5th. Chardan Capital dropped their price target on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Monday, April 6th. Finally, Citizens Jmp upgraded shares of Iovance Biotherapeutics from a “market perform” rating to a “market outperform” rating and set a $5.00 price objective on the stock in a research report on Tuesday, March 3rd. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $8.43.

Iovance Biotherapeutics Stock Down 0.9%

NASDAQ IOVA opened at $4.21 on Tuesday. Iovance Biotherapeutics has a 52 week low of $1.67 and a 52 week high of $5.63. The company has a market capitalization of $1.88 billion, a P/E ratio of -4.43 and a beta of 0.73. The stock’s 50-day moving average price is $3.86 and its 200-day moving average price is $3.38.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.19). The business had revenue of $71.43 million during the quarter, compared to analyst estimates of $77.84 million. Iovance Biotherapeutics had a negative return on equity of 50.17% and a negative net margin of 123.92%.Iovance Biotherapeutics’s revenue for the quarter was up 44.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.36) earnings per share.

Institutional Investors Weigh In On Iovance Biotherapeutics

A number of institutional investors have recently added to or reduced their stakes in IOVA. KBC Group NV purchased a new position in shares of Iovance Biotherapeutics in the first quarter worth $34,000. Arcataur Capital Management LLC purchased a new position in Iovance Biotherapeutics during the fourth quarter valued at $29,000. Granite Investment Partners LLC purchased a new position in Iovance Biotherapeutics during the fourth quarter valued at $29,000. Motley Fool Asset Management LLC bought a new stake in Iovance Biotherapeutics in the 4th quarter valued at $29,000. Finally, Sanctuary Advisors LLC bought a new stake in Iovance Biotherapeutics in the 1st quarter valued at $38,000. 77.03% of the stock is owned by hedge funds and other institutional investors.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.